

AUTHOR CORRECTION **OPEN**Author Correction: Cellular and molecular synergy in AS01-
adjuvanted vaccines results in an early IFN γ response
promoting vaccine immunogenicity

Margherita Coccia¹, Catherine Collignon¹, Caroline Hervé¹, Aurélie Chalon¹, Iain Welsby², Sophie Detienne², Mary J. van Helden³, Sheetij Dutta⁴, Christopher J. Genito⁴, Norman C. Waters⁴, Katrijn Van Deun^{5,6}, Age K. Smilde⁷, Robert A. van den Berg¹, David Franco¹, Patricia Bourguignon¹, Sandra Morel¹, Nathalie Garçon¹, Bart N. Lambrecht³, Stanislas Goriely², Robbert van der Most¹ and Arnaud M. Didierlaurent¹

npj Vaccines (2018)3:13; doi:10.1038/s41541-018-0047-7

Correction to: npj Vaccines (2017). <https://doi.org/10.1038/s41541-017-0027-3>; Published 8 September 2017

In the original version of the article, Fig. 2b was mislabelled. The second row was incorrectly labelled as “ $Mi_{MPL} > Mi_{PBS}$ and $Mi_{QS} \approx M_{PBS}$ ” this has now been corrected to “ $Mi_{QS-21} > Mi_{PBS}$ and $Mi_{MPL} \approx Mi_{PBS}$ ”. The third row was incorrectly labelled as “ $Mi_{QS21} > Mi_{PBS}$

and $Mi_{MPL} \approx Mi_{PBS}$ ” this has now been corrected to “ $Mi_{MPL} > Mi_{PBS}$ and $Mi_{QS-21} \approx Mi_{PBS}$ ”. These errors have now been corrected in the PDF and HTML versions of this article.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2018

b)

	$(Mi_{AS01} - Mi_{PBS}) < (Mi_{MPL} - Mi_{PBS})$ + $(Mi_{QS-21} - Mi_{PBS})$	$(Mi_{AS01} - Mi_{PBS}) \approx (Mi_{MPL} - Mi_{PBS})$ + $(Mi_{QS-21} - Mi_{PBS})$	$(Mi_{AS01} - Mi_{PBS}) > (Mi_{MPL} - Mi_{PBS})$ + $(Mi_{QS-21} - Mi_{PBS})$
$Mi_{MPL} > Mi_{PBS}$ and $Mi_{QS-21} > Mi_{PBS}$	ANTAGONISM <i>(725; 2154; 2253)</i>	ADDITIVE <i>(620; 2503; 3080)</i>	SYNERGY <i>(1; 7; 19)</i>
$Mi_{QS21} > Mi_{PBS}$ and $Mi_{MPL} \approx Mi_{PBS}$	INHIBITORY by MPL <i>(52; 331; 135)</i>	IRRELEVANCE of MPL <i>(1643; 3673; 3332)</i>	POTENTIATION by MPL <i>(27; 469; 785)</i>
$Mi_{MPL} > Mi_{PBS}$ and $Mi_{QS-21} \approx Mi_{PBS}$	INHIBITORY by QS-21 <i>(115; 97; 105)</i>	IRRELEVANCE of QS-21 <i>(1233; 4808; 5613)</i>	POTENTIATION by QS-21 <i>(29; 530; 946)</i>
$Mi_{MPL} \approx Mi_{PBS}$ and $Mi_{QS-21} \approx Mi_{PBS}$	(not possible)	(not possible)	EMERGENT <i>(71; 228; 557)</i>

Fig. 2b A taxonomy of possible interplays between QS-21 and MPL in AS01 is shown. The conditions to be met for each category are represented in bold. Mi represents the gene expression level for each gene i . Numbers in italics represent the number of AS01 DEGs belonging to each category at 2 h, 4 h, and 6 h after immunization, respectively

¹GSK Vaccines, Rixensart, Belgium; ²Institute for Medical Immunology, Université libre de Bruxelles, Gosselies, Belgium; ³Vlaams Instituut voor Biotechnologie, Inflammation Research Center, Ghent University, Ghent, Belgium; ⁴Malaria Vaccine Branch, Military Malaria Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA; ⁵Department of Methodology and Statistics, Tilburg University, Tilburg, The Netherlands; ⁶Department of Psychology, Katholieke Universiteit Leuven, Leuven, Belgium and ⁷Biosystems Data Analysis, Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands
Correspondence: Arnaud M. Didierlaurent (arnaud.x.didierlaurent@gsk.com)

Published online: 21 March 2018

Published in partnership with the Sealy Center for Vaccine Development